Translational Neural Devices (U44 Clinical Trial Optional)

0
2

Funding Opportunity ID:333155
Opportunity Number:RFA-NS-21-022
Opportunity Title:Translational Neural Devices (U44 Clinical Trial Optional)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Health
Category Explanation:
CFDA Number(s):93.853
Eligible Applicants:Small businesses
Additional Information on Eligibility:Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Apr 28, 2021
Close Date:Feb 20, 2024
Last Updated Date:Apr 28, 2021
Award Ceiling:$1,000,000
Award Floor:$0
Estimated Total Program Funding:$4,000,000
Expected Number of Awards:
Description:The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design.
Version:1





Visit the Official Webpage For More Details on Translational Neural Devices (U44 Clinical Trial Optional)

LEAVE A REPLY

Please enter your comment!
Please enter your name here